002107 沃华医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.5007.57413.70420.07124.183
总资产报酬率 ROA (%)1.0345.2369.49912.91015.044
投入资产回报率 ROIC (%)1.4697.40713.41917.75221.242

边际利润分析
销售毛利率 (%)72.21574.44475.27877.47177.834
营业利润率 (%)3.7396.21111.06720.44022.126
息税前利润/营业总收入 (%)2.7815.44710.47020.06321.475
净利润/营业总收入 (%)2.4345.1278.85717.11318.520

收益指标分析
经营活动净收益/利润总额(%)87.70896.089101.503102.36697.258
价值变动净收益/利润总额(%)0.0000.0000.0000.0003.143
营业外收支净额/利润总额(%)-5.919-3.389-1.373-1.437-0.976

偿债能力分析
流动比率 (X)1.9452.3372.1143.0461.875
速动比率 (X)1.4721.8191.5992.2321.604
资产负债率 (%)30.09427.18828.20019.96632.996
带息债务/全部投入资本 (%)-0.425-1.269-0.599-2.03517.155
股东权益/带息债务 (%)-22,900.456-7,754.132-16,202.462-4,847.630466.479
股东权益/负债合计 (%)223.406258.738240.651354.018178.596
利息保障倍数 (X)-3.714-9.715-23.373-228.748-49.171

营运能力分析
应收账款周转天数 (天)32.45339.07437.47439.87638.124
存货周转天数 (天)230.665228.542223.809237.783169.741